No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Vim Appoints Mike Leonard As CRO

Editor: What To Know

  • Mike joining our team is a real validation of the value Vim delivers to our members, payer customers, and provider partners,” said Oron Afek, CEO and Co-founder of Vim.
  • I am excited to build on their results with healthcare payers and thousands of providers across the country,” said Leonard.
  • Leonard's appointment comes on the heels of the company's $24M Series B financing and significant growth in customer and business operations.

Today Vim announced the expansion of its senior leadership team with the addition of Mike Leonard as the company’s Chief Revenue Officer (CRO).

Leonard’s appointment comes on the heels of the company’s $24M Series B financing and significant growth in customer and business operations. Leonard will lead all revenue-related functions, along with the company’s expansion to the technology hub of Boulder, Colorado.

“2019 was a watershed year in terms of our growth and evolution. With Mike’s two decades of technology and leadership experience, we are doubling down on expansion efforts to impact as many healthcare consumers as possible. Mike joining our team is a real validation of the value Vim delivers to our members, payer customers, and provider partners,” said Oron Afek, CEO and Co-founder of Vim. “As more payers and care providers integrate with Vim’s technology, we are able to significantly impact the total cost of care across the country – accelerating the promise of value-based care.”

Before joining Vim, Leonard was Chief Commercial Officer at Castlight Health leading all go-to-market teams for Castlight’s health navigation platform. During his tenure, he was responsible for record-breaking sales of digital health engagement and navigation solutions across employer and health plan channels. Prior to Castlight, Leonard was Executive Vice President of Sales and Marketing at Jiff, purchased by Castlight in April 2017.

“Vim’s critical infrastructure software for value-based care is simple to implement and easy to use for care providers and health plan members. I am excited to build on their results with healthcare payers and thousands of providers across the country,” said Leonard. “I am humbled to join such a fantastic mission-driven team, and I look forward to leading our growth across additional markets and membership segments.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy